Research programme: recombinant human biglycan - Tivorsan

Drug Profile

Research programme: recombinant human biglycan - Tivorsan

Alternative Names: Biglycan; rh-BGN; TVN-102

Latest Information Update: 16 Aug 2016

Price : $50

At a glance

  • Originator Brown University
  • Developer Tivorsan Pharmaceuticals
  • Class Proteoglycans
  • Mechanism of Action Utrophin activators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Duchenne muscular dystrophy
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Amyotrophic lateral sclerosis; Duchenne muscular dystrophy; Muscular dystrophies

Most Recent Events

  • 15 Aug 2016 Recombinant human biglycan - Tivorsan receives Orphan Drug status for Duchenne muscular dystrophy in USA
  • 15 Aug 2016 Tivorsan Pharmaceuticals announces intention to submit IND application for phase I trials of recombinant human biglycan, TVN 102
  • 17 Aug 2015 Preclinical trials in Muscular dystrophies (Congenital) in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top